HLB announced that a total of 16 meaningful clinical trials of Rivoceranib (Chinese name Apatinib) will be announced at the American Society of Clinical Oncology (ASCO), which will be held online from 29th to 31st.
Elevar, a US subsidiary of HLB, posterizes Phase 2 clinical trials of Adenoid Cystic Carcinoma (ACC). It relates to a global clinical trial evaluating the efficacy and safety of Rivoceranib for recurrent or metastatic adenocystic carcinoma, which is ongoing in the United States and Korea. In March, the first patient was enrolled at the University of California (UC San Francisco), Seoul National University, Korea. The Seoul Asan Hospital, Samsung Medical Center, and the National Cancer Center are also recruiting patients. Adenocarcinoma is rare cancer and there is no worthy treatment, so if the clinical trial result of Rivoceranib is good, it is expected to be designated as an innovative drug.
Chinese anti-pharmaceuticals also verbally report the results of phase 3 of hepatocellular carcinoma, which has been conducted with Rivoceranib alone. In China, a randomized, double-blind, comparative clinical phase 3 trial was conducted in patients who failed primary treatment for hepatocellular carcinoma through Nexavar.
As a result of the clinical trial, the median survival period (mOS) was 8.7 months, showing statistical significance compared to the control group of 6.8 months. It showed statistically significant results. The objective response rate (ORR) also showed an excellent effect of 10.7% in the Rivoceranib group and 1.5% in the control group. In March, the anti-pharmaceutical drug was applied to Chinese NMPA as a secondary treatment for liver cancer with Rivoceranib monotherapy.
HLB will receive royalties from this year on a sales basis last year as it acquired the global rights of Rivoceranib from Advenchen Research Institute. Following sales of KRW 370 billion (KRW 2.1 billion), it is expected that royalties will increase further when the market is licensed for liver cancer.
In addition, the results of an additional 14 clinical trials by researchers, including cervical cancer, soft tissue sarcoma, biliary tract cancer, breast cancer, melanoma, non-small cell lung cancer, and small cell lung cancer, will be presented as posters.
"After last year's announcement of the third phase of Rivoceranib gastric cancer at ESMO, we were able to confirm the efficacy of Rivoceranib in various indications again at this ASCO," said Bok-Hwan Jeon, the President of biotechnology of HLB. "The development of Phase 2 and Corona19 vaccines and the sale of Apealea in Europe, an ovarian cancer treatment that has acquired global rights, is also progressing as planned.